Physician profile
Michelle E Weiner
NPI 1568634293
$6,388.02
in general payments reported to CMS, 2019-2025
35 companies · $541 in 2025
The $541 reported for 2025 was more than what 80% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $414 · 2021: $1,000 · 2022: $1,452 · 2023: $1,376 · 2024: $1,048 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $1,115.58 | 2019-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $1,095.62 | 2019-2025 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $608.76 | 2019-2025 | Relistor |
| Abbvie INC. | $335.67 | 2021-2024 | Botox |
| Allergan, INC. | $332.57 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $290.00 | 2024-2025 | Spravato |
| Pfizer INC. | $258.11 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $254.70 | 2022 | |
| Amgen INC. | $177.35 | 2019-2020 | |
| Redhill Biopharma INC. | $166.49 | 2020-2021 | |
| Vgi Medical, LLC | $162.13 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $158.85 | 2019-2023 | |
| Grt US Holding, INC. | $144.81 | 2022 | |
| Forte Bio-Pharma LLC | $144.46 | 2021-2023 | Prolate, Nalocet |
| Almatica Pharma LLC | $137.10 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $122.97 | 2022 | |
| Idorsia Pharmaceuticals US INC | $102.29 | 2022-2024 | Quviviq |
| Merz Pharmaceuticals, LLC | $87.64 | 2021-2022 | |
| Valinor Pharma, LLC | $82.51 | 2023-2025 | Movantik |
| Boston Scientific Corporation | $82.31 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $70.01 | 2024 | Horizant |
| Protega Pharmaceutials INC | $64.47 | 2022-2025 | Roxybond |
| Kowa Pharmaceuticals America, INC. | $59.77 | 2022 | |
| Averitas Pharma INC. | $55.83 | 2023 | Qutenza |
| Virtus Pharmaceuticals LLC | $44.41 | 2021 | |
| Mdd US Operations, LLC | $37.43 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $27.13 | 2024 | Givlaari |
| Vertex Pharmaceuticals Incorporated | $25.69 | 2025 | |
| Masimo Corporation | $25.00 | 2023 | Patient Safetynet System |
| Medline Industries LP | $23.99 | 2022 | |
| Indivior INC. | $23.10 | 2025 | Sublocade |
| Novartis Pharmaceuticals Corporation | $22.73 | 2019 | |
| Ibsa Pharma INC. | $17.90 | 2023 | Tirosint, Licart |
| Nevro Corp. | $17.37 | 2019 | |
| Medtronic, INC. | $13.27 | 2023 | Vanta Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.